1. Search Result
Search Result
Results for "

Sj?gren's syndrome (SS)

" in MedChemExpress (MCE) Product Catalog:

7223

Inhibitors & Agonists

34

Screening Libraries

61

Fluorescent Dye

166

Biochemical Assay Reagents

553

Peptides

5

MCE Kits

63

Inhibitory Antibodies

743

Natural
Products

574

Recombinant Proteins

566

Isotope-Labeled Compounds

176

Antibodies

134

Click Chemistry

Cat. No. Product Name Target Research Area
  • HY-P99459

    BG 9924; TT-47

    Inhibitory Antibodies Inflammation/Immunology
    Baminercept (BG 9924) is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig). Baminercept can be used for the research of many autoimmune diseases including primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) .
  • HY-P99365

    ALXN1210

    Complement System Metabolic Disease
    Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
  • HY-P99506

    SC-003 mAb; SC-Mab003; SC34.28ss1

    ADC Antibody Cancer
    Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .
  • HY-P990387

    Inhibitory Antibodies Inflammation/Immunology
  • HY-108794

    BMN 110; Chondrosulfatase; Chondroitinase; Chondrosulfatases; Chondroitin sulfatase

    Inhibitory Antibodies Others
    Elosulfase alfa (BMN 110) is a recombinant form of human N-acetylgalactosamine-6-sulfatase (GALNS). Elosulfase alfa is used as an enzyme replacement therapy for mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome .
  • HY-108822

    Arcalyst; IL 1 Trap; Interleukin 1 Trap

    Interleukin Related Inflammation/Immunology
    Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
  • HY-P99050

    Complement System Cardiovascular Disease Inflammation/Immunology
    Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase .
  • HY-P99988

    Inhibitory Antibodies Inflammation/Immunology
    Human IgG4 (S228P) kappa, Isotype Control, a human-mouse chimeric monoclonal antibody, is an isotype control for human IgG4 (S228P)κ antibody.
  • HY-P99810

    AVTX-002; AEVI 002; SAR 252067

    SARS-CoV Cardiovascular Disease
    Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
  • HY-P9975

    TGN1412

    CD28 Inflammation/Immunology
    Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
  • HY-P99622

    IMC-20D7S

    Tyrosinase Cancer
    Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
  • HY-P99993

    Inhibitory Antibodies Inflammation/Immunology
    Human IgG1 (S239D/I332E) kappa, Isotype Control, a human-mouse chimeric monoclonal antibody, is an isotype control for Human IgG1 (S239D/I332E)κ antibody.
  • HY-P99309

    BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody

    Bacterial Infection
    Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
  • HY-P99987

    Inhibitory Antibodies Inflammation/Immunology
    Human IgG4 (S228P) lambda1, Isotype Control, a human-mouse chimeric monoclonal antibody, is an isotype control for human IgG4 (S228P) λ1 antibody.
  • HY-P990296

    Inhibitory Antibodies Others
    Anti-Mouse CCR3/CD193) Antibody (6S2-19-4) is a rat-derived IgG2b, λ type antibody inhibitor, targeting to mouse CCR3/CD193).
  • HY-P990111

    TNF Receptor Inflammation/Immunology
    BMS-986325 (anti-CD40) is a CD40 inhibitor, and can be used for primary Sjögren's syndrome research .
  • HY-P99623

    MGD006; S80880

    CD3 Cancer
    Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
  • HY-P990193

    Inhibitory Antibodies Others
    Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse MHC Class I.
  • HY-P990185

    Inhibitory Antibodies Others
    Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/rat MHC Class II.
  • HY-P99318

    LT 1009; Anti-Human S1P Recombinant Antibody

    LPL Receptor Cancer
    Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
  • HY-P99463

    AVB-S6-500

    TAM Receptor Cancer
    Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
  • HY-P99555

    OPN-305

    Toll-like Receptor (TLR) Inflammation/Immunology
    Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS) .
  • HY-P990191

    Inhibitory Antibodies Others
    Anti-Mouse MHC Class I (H-2Kk, H-2Dk) Antibody (15-3-1S (HB-13)) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse MHC Class I.
  • HY-P99889

    BRII-198

    SARS-CoV Infection
    Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
  • HY-P99414

    AMG 557

    Inhibitory Antibodies Inflammation/Immunology
    Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .
  • HY-P99581

    OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01

    Wnt Cancer
    Tabituximab barzuxetan (exclude Y90) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research .
  • HY-P99445

    APG101; CAN008

    TNF Receptor Inflammation/Immunology Cancer
    Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
  • HY-P990490

    Inhibitory Antibodies Inflammation/Immunology
  • HY-P990091

    SAR 445088

    Complement System Inflammation/Immunology
    Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .
  • HY-P99384

    B-701; MFGR-1877S; RG-7444

    FGFR Cancer
    Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC) .
  • HY-P99770

    514-G3

    Bacterial Infection
    Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
  • HY-P99556

    AZD8895

    SARS-CoV Infection
    Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
  • HY-P9957

    ABthrax

    Bacterial Infection
    Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
  • HY-P99185

    Amyloid-β Neurological Disease
    Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
  • HY-P99292

    HuZAF; Anti-Human IFNG Recombinant Antibody

    IFNAR Inflammation/Immunology
    Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
  • HY-P99551

    KBSA301; AR-301

    Antibiotic Infection
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
  • HY-P99317

    Immunoglobulin G1, anti-(human β-amyloid) (human-mouse monoclonAnti-Human Abeta Recombinant Antibody

    Amyloid-β Neurological Disease
    Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease .
  • HY-P99703

    17.1.41

    HBV Infection
    Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
  • HY-P99104

    COVI-AMG; STI-2020

    SARS-CoV Infection
    Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
  • HY-P990052

    MAD-0004J08

    SARS-CoV Infection
    Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
  • HY-145641

    BMS-986413; C-144-LS

    SARS-CoV Infection
    Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .
  • HY-P99471

    UCB 0107

    Tau Protein Neurological Disease
    Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .
  • HY-P99109

    GLS-010; AB-122; WBP-3055

    PD-1/PD-L1 Cancer
    Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
  • HY-P99499

    JNJ 63723283; JNJ 3283

    PD-1/PD-L1 Interleukin Related TNF Receptor Cancer
    Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
  • HY-P99491

    AVTX-007; CERC-007; MEDI 2338

    Interleukin Related Inflammation/Immunology
    Camoteskimab (AVTX-007) is a fully human, high-affinity anti-IL-18 monoclonal antibody. Camoteskimab has the potential for the autoinflammatory diseases research, including adult-onset Still’s disease (AOSD) .
  • HY-P99952

    SCT400

    CD20 Cancer
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
  • HY-P99273

    Anti-Human CD70 Recombinant Antibody

    Inhibitory Antibodies Cancer
    Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
  • HY-P99648

    BMS-986168; IPN007; BIIB092

    Tau Protein Neurological Disease
    Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
  • HY-P9807

    SARS-CR3022; SARS-CoV-2 Antibody-CR3022

    SARS-CoV Infection Inflammation/Immunology
    Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
  • HY-P99467

    BMS 4182137; VIR 7832

    SARS-CoV Infection
    Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: